We rank companies based on fund manager, research analyst and news sentiment
HBIO stock icon

Harvard Bioscience


About: Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.

Employees: 416

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

24% more capital invested

Capital invested by funds: $142M [Q3] → $175M (+$33.6M) [Q4]

14% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 28

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

0.42% less ownership

Funds ownership: 77.15% [Q3] → 76.73% (-0.42%) [Q4]

3% less funds holding

Funds holding: 94 [Q3] → 91 (-3) [Q4]

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Research analyst outlook

We haven’t received any recent analyst ratings for HBIO.

Financial journalist opinion